Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Zacks Research

Delcath Systems (NASDAQ:DCTH) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price (up from $30.00) on shares of Delcath Systems in a research note on Friday. Wall Street Zen upgraded shares of Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday. BTIG Research raised their price target on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.17.

Delcath Systems Price Performance

NASDAQ DCTH opened at $17.22 on Monday. The stock’s 50 day simple moving average is $12.61 and its 200-day simple moving average is $10.97. The company has a market cap of $597.53 million, a PE ratio of 1,723.72 and a beta of 0.52. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $17.42.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.16. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%.The firm had revenue of $29.13 million during the quarter, compared to analysts’ expectations of $26.25 million. On average, equities research analysts anticipate that Delcath Systems will post -0.17 EPS for the current fiscal year.

Institutional Trading of Delcath Systems

Several institutional investors and hedge funds have recently bought and sold shares of DCTH. Millennium Management LLC lifted its position in Delcath Systems by 34.1% in the first quarter. Millennium Management LLC now owns 422,066 shares of the company’s stock valued at $5,373,000 after buying an additional 107,391 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Delcath Systems by 58.7% during the first quarter. Goldman Sachs Group Inc. now owns 123,487 shares of the company’s stock valued at $1,572,000 after acquiring an additional 45,695 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Delcath Systems by 229.1% during the second quarter. JPMorgan Chase & Co. now owns 168,245 shares of the company’s stock valued at $2,288,000 after acquiring an additional 117,118 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of Delcath Systems in the 2nd quarter valued at approximately $46,000. Finally, Rhumbline Advisers purchased a new stake in shares of Delcath Systems in the 2nd quarter valued at approximately $586,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems News Roundup

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $32 price target while sharply raising its EPS forecasts. The firm now expects a smaller FY2026 loss of $0.17 per share, versus its prior estimate of $0.88, followed by profitability in FY2027 at $0.12 per share. Longer-term estimates were also increased to $0.56 for FY2028, $0.97 for FY2029 and $1.46 for FY2030, suggesting improved confidence in Delcath’s earnings trajectory. MarketBeat analyst estimates
• Positive Sentiment: Zacks highlighted DCTH as a potential momentum stock, citing favorable price momentum and improving earnings-estimate revisions. Another Zacks analysis said Wall Street analysts see potential upside of approximately 42.8%, although price-target projections are not guaranteed. Zacks momentum stock analysis Zacks price target analysis
• Neutral Sentiment: Reported short interest was zero shares both on August 11 and July 27, producing a zero-day short-interest ratio. Because the report also shows an invalid “NaN” change, the data provides no meaningful indication of short-covering or bearish pressure.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.